GlassScriptPhysician profile
Ramona Boyd
NPI 1871815316
$4,437.61
in general payments reported to CMS, 2019-2025
19 companies · $2,193 in 2025
The $2,193 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $416 · 2022: $341 · 2023: $412 · 2024: $1,076 · 2025: $2,193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,634 · Education: $46.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,633.99 |
| Education | $46.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,675.91 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $846.39 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $476.09 | 2023-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $202.06 | 2024-2025 | Spravato |
| Novo Nordisk INC | $201.93 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $169.79 | 2025 | Freestyle Libre 3 |
| Axsome Therapeutics, INC. | $159.31 | 2024-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $148.97 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $135.95 | 2024-2025 | Uzedy, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $104.75 | 2023-2025 | Rexulti |
| Pfizer INC. | $73.27 | 2023-2024 | |
| Kyowa Kirin, INC. | $57.81 | 2025 | |
| Lilly USA, LLC | $44.56 | 2022-2025 | Mounjaro, Zepbound |
| Uswm, LLC | $35.65 | 2024 | Lucemyra |
| Biohaven Pharmaceuticals, INC. | $25.26 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $24.66 | 2024 | Nuplazid |
| Biohaven Pharmaceutical Holding Company LTD. | $18.80 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.49 | 2025 | Trintellix |
| Allergan, INC. | $17.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramona Boyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.